Cyteir Therapeutics (NASDAQ:CYT) reported quarterly losses of $(4.83) per share. This is a 51.89 percent decrease over losses of $(3.18) per share from the same period last year.
Needham Maintains Buy on Extreme Networks, Raises Price Target to $14.5
Needham analyst Alex Henderson maintains Extreme Networks (NASDAQ:EXTR) with a Buy and raises the price target from $13.5 to $14.5.
